RankAlpha logo
Back to Rankings

DYN

Dyne TherapeuticsF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Positive pivotal/registrational readouts and a strategic partner would validate Dyne’s delivery platform, supporting a recovery toward prior highs and a re‑rating to the bull target.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +12.1.
What can break
Clinical trial failure or negative readouts
Momentum
85
Value
41
Sentiment
0
Setup hits (3d)
— · Net —
AI TargetsBase $8.00 · Bull $12.00 · Bear $5.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-26 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net —
Target $38.25
Why
Momentum85 · Δ7d +12.1
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture. Prioritize risk control and patience.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
85
26% active weight
Current posture
7d trendImproving
Δ7d
+12.1
Δ21d
+19.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade

Composite grade F. Momentum 84.8 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.92B
Beta
1.31
Shares Out
165.31M
P/E (TTM) · Derived
-6.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.31
Rev YoY
-
EPS YoY
-30.2%
Gross Margin
-
Op Margin
-
Net Debt
-$941.36M
Current Ratio
19.92
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology